| Literature DB >> 33349888 |
Sonja Dorfer1, Katharina Strasser, Siegfried Reipert, Michael B Fischer, Saeed Shafti-Keramat, Michael Bonelli, Georg Schröckenfuchs, Wolfgang Bauer, Stefanie Kancz, Lena Müller, Alessandra Handisurya.
Abstract
Cathelicidins have been reported to inhibit human papillomavirus infection in vitro; however, nothing is known about their activity in vivo. In this study, experimental skin infection with Mus musculus papillomavirus 1 resulted in robust development of cutaneous papillomas in cyclosporine A-treated C57BL/6J mice deficient for the murine cathelicidin-related antimicrobial peptide (CRAMP), in contrast to wild-type controls. Analysis of the underlying mechanisms revealed moderate disruption of virion integrity and lack of interference with viral entry and intracellular trafficking by a synthetic CRAMP peptide. Differences in the immune response to Mus musculus papillomavirus 1 infection were observed between CRAMP-deficient and wild-type mice. These included a stronger reduction in CD4+ and CD8+ T-cell numbers in infected skin, and lack of Mus musculus papillomavirus 1-specific neutralizing antibodies in response to cyclosporine A in the absence of endogenous CRAMP. CRAMP has modest direct anti-papillomaviral effects in vitro, but exerts protective functions against Mus musculus papillomavirus 1 skin infection and disease development in vivo, primarily by modulation of cellular and humoral immunity.Entities:
Keywords: CRAMP; MmuPV1; antiviral mechanisms; cathelicidin; skin papilloma; antimicrobial peptide
Mesh:
Substances:
Year: 2021 PMID: 33349888 PMCID: PMC9309842 DOI: 10.2340/00015555-3733
Source DB: PubMed Journal: Acta Derm Venereol ISSN: 0001-5555 Impact factor: 3.875